Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Company release
Herantis Pharma Plc, Company release, 3 October 2025 at 14:30 p.m. EEST
Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Herantis Pharma Plc (“Herantis”) has, on 3 October 2025, received a notification from Kyösti Kakkonen in accordance with chapter 9, section 10 of the Securities Market Act. According to the notification, holdings of Kyösti Kakkonen in Herantis have exceeded the level of 10 per cent, as a result of share transactions concluded on 3 October 2025.
Herantis has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date of the notification received by Herantis.
| Total positions of Kyösti Kakkonen subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 10.055498 | 10.055498 | 24,094,817 | |
| Position of previous notification (if applicable) | 9.7905952 | 9.7905952 | 24,094,817 | |
| Notified details of the resulting situation on the date on which the threshold was crossed or reached: | ||||
| A: Shares and voting rights | ||||
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI4000087861 | 0 | 2,422,854 | 10.055498 | |
| SUBTOTAL A | 2,422,854 | 10.055498 | ||
| Information in relation to the person subject to the notification obligation | |||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | |||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
| Kyösti Kakkonen | 0.087156 | 0 | 0.087156 |
| K22 Finance Oy* | 1.102992 | 0 | 1.102992 |
| Joensuun Kauppa ja Kone Oy** | 8.865350 | 0 | 8.865350 |
*Kyösti Kakkonen holds 77.78 per cent of K22 Finance Oy.
**Kyösti Kakkonen holds 55.3 per cent of Kakkonen-Yhtiöt Oy, which holds 100 per cent of Joensuun Kauppa ja Kone Oy.
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Ltd
Tel.: +358 9 25 380 225
E-mail: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. HER-096 is currently being evaluated in a Phase 1b clinical trial to assess the safety and tolerability of repeated subcutaneous dosing in patients with Parkinson’s disease. The study builds on positive Phase 1a results, where HER-096 demonstrated a favourable safety and tolerability profile, and effective brain penetration in healthy volunteers.
Herantis is listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com